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Abstract
Background: Patients with small-sized peripheral non-small cell lung cancer (NSCLC), but without lymph node
metastasis, may be optimal candidates for sublobar resection. We aim to identify the predictors of occult lymph
node metastasis (OLNM) using F-18 fluorodeoxyglucose positron emission tomography/computed tomography
(PET/CT) in clinically node-negative, small-sized NSCLC.
Methods: One hundred thirty nine patients with small-sized NSCLC (of less than 3 cm in diameter) who underwent
surgical resection with mediastinal lymph node dissection were evaluated. The maximum standardized uptake value
(SUVmax), metabolic total volume (MTV) and total lesion glycolysis (TLG) of the primary tumor were measured on
pretreatment PET/CT. These metabolic parameters and pathological variables were analyzed for OLNM.
Results: The mean tumor size was 2.11 ± 0.63 cm, and the mean number of dissected lymph nodes was 19.74 ± 12.86.
Adenocarcinoma occurred in 106 patients (76.3 %). Twenty-four patients (17.2 %) had lymph node metastasis. The
mean SUVmax, MTV and TLG were 4.61 ± 3.99 (0.5 ~ 17.8), 4.18 ± 6.39 (0 ~ 34.6) and 16.13 ± 28.86 (0 ~ 164.2), respectively.
On receiver operating characteristic (ROC) curve analysis, the areas under the curve (AUC) for SUVmax, MTV and TLG for
node metastasis were 0.753, 0.783 and 0.775, respectively. On multivariate analysis, SUVmax (Odds ratio [OR] = 1.120,
p = 0.044) and MTV (OR = 1.117, p = 0.007) were found to be risk factors for OLNM. The concordance index of MTV was
0.763, which was slightly higher than that of SUVmax.
Conclusion: SUVmax and volume-based parameters are significant risk factors for OLNM in small peripheral NSCLC. MTV
showed a better predictive performance than that of the other PET parameters; therefore, MTV may be a possible
indicator for sublobar resection in clinically node-negative small-sized NSCLC.
Keywords: Non-small cell lung cancer, Fluorine 18-fluorodeoxyglucose (FDG), Positron emission tomography/computed
tomography (PET/CT), Lymph node metastasis, Metabolic tumor volume
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Background
The early detection of small-sized non-small cell lung
cancer (NSCLC) has increased due to recent advances in
radiographic technologies, such as high-resolution com-
puted tomography (CT) and the widespread use of low-
dose helical CT for screening [1–3]. Even though ana-
tomic resection, such as lobectomy and mediastinal
lymph node dissection, is the surgical treatment of
choice for NSCLC, sublobar resections such as segmen-
tectomy and wedge resection have also been performed
to preserve lung function. Several studies have reported
that the survival duration is similar between patients
with small peripheral NSCLC treated with segmentectomy
versus lobectomy [4–7]. In determining the indications for
sublobar resection, prediction of the pathological node-
negative (pN0) status is an important factor; if nodal me-
tastasis is present, lobectomy and mediastinal lymph node
dissection rather than sublobar resection are mandatory.
According to previous studies, tumor size, SUVmax on
PET/CT and tumor type, such as adenocarcinoma, have
been suggested as risk factors for node metastasis in early
NSCLC [8].
18F-fluorodeoxyglucose positron emission tomography
(FDG PET) is a valuable imaging modality for staging,
management and predicting the prognosis of NSCLC.
FDG PET parameters, standardized uptake value (SUV),
metabolic tumor volume (MTV) and total lesion gly-
colysis (TLG), can provide useful data on tumor metab-
olism. Whereas the maximum SUV (SUVmax) is the
value of a single voxel with the highest radiotracer con-
centration within the tumor, volume-based parameters
such as MTV and TLG indicate tumor burden. There
has been a growing interest in the clinical significance of
volume-based parameters for NSCLC. Studies have shown
that volume parameters are a better index of patient prog-
nosis than is SUVmax in advanced NSCLC [9–11]. In
addition, recent studies have shown that volume parame-
ters are also a significant prognostic factor in early stage
NSCLC [12–14]. The most recent study reported the
prognostic role of TLG in stage IA NSCLC [14]. Based on
these previous studies regarding PET volume parameters,
we hypothesized that the volume parameter of FDG PET
can also predict node metastasis in early NSCLC. Even
though several studies have reported that the SUV-
max of a primary tumor is a significant predictor of
node metastasis in clinical stage IA lung cancer [8,
15], there have been few studies using volume-based
parameters for detecting occult node metastasis in
early-stage lung cancer.
In this study, therefore, we investigated the risk factors
for node metastasis in clinically node-negative, small
peripheral NSCLC. The predictive roles of PET parame-
ters, SUVmax and volume-based parameters were also
evaluated and were compared using statistical methods.
Methods
Patients
We retrospectively reviewed the medical records of 440
consecutive NSCLC patients who underwent both pre-
treatment FDG PET/CT and surgery between January
2010 and June 2015 at the Ajou Medical Center. All pa-
tients underwent chest CT, bronchoscopy, FDG PET/CT
and brain magnetic resonance imaging for staging work-
up. The primary tumor size was measured on chest CT
images. The inclusion criteria were a small NSCLC of
less than 3 cm, located in the outer one-third of the lung
parenchyma, with no enlargement of the interlobar, hilar
or mediastinal lymph nodes on chest CT and no sig-
nificant FDG uptake in the lymph nodes except for
the primary lesion. We subsequently evaluated 139
patients with small-sized and peripheral NSCLC. The
ethics committee of our institution approved this
retrospective study (IRB No. MED-MDB-13-391), and
requirement for informed consent was waived.
FDG PET-CT protocol
FDG PET/CT was performed using two types of PET/
CT scanners: the Discovery ST and the Discovery STE
(GE healthcare, Milwaukee, WI, USA). All patients
fasted for at least 6 hours before scanning; serum glu-
cose levels at the time of FDG injection were < 150 mg/
dl. Unenhanced CT was performed 60 min after a
5 MBq/kg FDG injection using 8- or 16-slice helical CT
(120 keV, 30–100 mA in AutomA mode; section
width = 3.75 mm). Emission PET data was acquired
from the thigh to the head for 2.5 min per frame in
the three-dimensional mode. Attenuation-corrected
PET images using CT data were reconstructed by an
ordered-subsets expectation maximization algorithm
(20 subsets, 2 iterations).
Measurement of PET parameters
The measurement of PET parameters was performed
using a dedicated workstation (GE Advantage Worksta-
tion 4.4; GE Healthcare). We measured the various PET
parameters of the primary lung lesion. Volume viewer
software, which represents the volume of interest (VOI)
automatically delimited by an isocontour threshold
method based on the SUV, was used to calculate
metabolic parameters including SUVmax, average
SUV (SUVavg), MTV and TLG. The SUVmax was
defined as the voxel with the highest count within
the VOI. Fixed SUV values (1.5, 2.0, 2.5 and 3.0)
were used to define VOI boundaries. MTVs were
automatically calculated by summing the total vol-
umes of voxels with threshold SUVs of 1.5, 2.0, 2.5
and 3.0 in the VOI, respectively. TLG was calculated
by multiplying the SUVavg by the MTV.
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Statistical analysis
Statistical analysis was performed using the open source
statistical software R (http://www.R-project.org). Clinical
and pathological parameters were described as means ±
standard deviations of the mean for continuous variables
and as frequencies (%) for categorical variables. For the
purpose of statistical analysis, clinical variables were
grouped into two categories with the exception of tumor
size, PET parameters and the number of dissected lymph
nodes. Receiver operating characteristic (ROC) analysis
was performed to calculate the area under the ROC
curve (AUC) for each PET parameter. Univariate and
multivariate logistic regression models were used to
identify the risk factors for occult nodal metastasis. Odds
ratios (ORs) with 95 % confidence intervals (CIs) were
determined in the multivariate logistic regression model.
Preoperative predictors with a p < 0.25 in the univariate
analysis were entered into a multivariate logistic regres-
sion model. The “PredictABEL” packages of R software
for performance assessment, calculation of concordance
index (C-index) and comparison of several multivariate
logistic regression models were used for analyses [16].
All p-values were two-sided, and p < 0.05 was considered
significant.
Results
Patient demographics and preoperative PET analysis
The demographic data of the patients included in this
study are listed in Table 1. Of the 139 patients who were
evaluated retrospectively, 80 (57.6 %) were male and 59
(42.4 %) were female, with a mean age of 62.82 ±
10.04 years. The mean whole tumor size was 2.11 ±
0.63 cm. The majority of patients underwent anatomic
resection (lobectomy or above). The mean number of
dissected lymph nodes was 19.74 ± 12.86. The number
of adenocarcinomas was 106 (76.3 %). Twenty-four pa-
tients (17.2 %) had lymph node metastasis; 12 (8.6 %)
were N1 and 12 (8.6 %) were N2. The general character-
istics between patients with pathologic N0 and patients
with pathologic N1, 2 were not significantly different
(Table 1). Figure 1 shows representative PET/CT images
of occult lymph node metastasis in small-sized periph-
eral NSCLC.
ROC curve analysis was performed to define the
optimal cut-off value for measuring the volume-based
parameters. Because the AUCs of MTV and TLG mea-
sured using a fixed SUV value of 2.0 were higher than
the AUCs of MTV and TLG measured using a fixed
SUV value of 1.5, 2.5 and 3.0, MTV and TLG measured
Table 1 General characteristics of 139 patients
Variables All patients (n = 139) Pathologic N0 (n = 115) Pathologic N1 and N2 (n = 24) pa
Age (years) 62.82 ± 10.04 (35 ~ 84) 62.90 ± 10.0 62.46 ± 10.44 0.847
Gender (Male/Female) 80 (57.6 %)/59 (42.4 %) 63 (54.8 %)/52 (45.2 %) 17 (70.8 %)/7 (29.2 %) 0.177
Dissected lymph nodes 19.74 ± 12.86 19.12 ± 12.98 22.67 ± 12.07 0.222
Tumor size (cm) 2.11 ± 0.63 2.05 ± 0.64 2.38 ± 0.57 0.023
Location 0.775
RUL/RML/RLL 54 (38.9 %)/19 (13.7 %)/28 (20.1 %) 46 (40.0 %)/17 (14.8 %)/22 (19.1 %) 8 (33.3 %)/2 (8.3 %)/6 (25.0 %)
LUL/LLL 26 (18.7 %)/12 (8.6 %) 20 (17.4 %)/10 (8.7 %) 6 (25.0 %)/2 (8.3 %)
Type of operation 0.161
Wedge resection/Segmentectomy 10 (7.2 %)/2 (1.4 %) 10 (8.7 %)/1 (0.9 %) 0/1 (4.2 %)
Lobectomy or above 129 (91.4 %) 104 (90.4 %) 23 (95.8 %)
Pathology 0.290
Adenocarcinoma 106 (76.3 %) 90 (78.3 %) 16 (66.7 %)
Non-adenocarcinoma 33 (23.7 %) 25 (21.7 %) 8 (33.3 %)
Differentiation 0.317
Well differentiated 32 (23.1 %) 29 (25.2 %) 3 (12.5 %)
Moderate differentiated 56 (43.3 %) 45 (39.2 %) 11 (45.8 %)
Poorly differentiated 17 (12.2 %) 12 (10.4 %) 5 (20.8 %)
Not defined 34 (24.4 %) 29 (25.2 %) 5 (20.8 %)
pT stage 0.627
T1a/T1b 43 (31.0 %)/33 (23.7 %) 37 (32.2 %)/28 (24.3 %) 6 (25.0 %)/5 (20.8 %)
T2a 63 (45.3 %) 50 (43.5 %) 13 (54.2 %)
acomparison between pathologic N0 and pathologic N1, 2
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using SUV 2.0 was adopted (Table 2). The mean SUV-
max, MTV and TLG were 4.61 ± 3.99 (0.5 ~ 17.8), 4.18 ±
6.39 (0 ~ 34.6) and 16.13 ± 28.86 (0 ~ 164.2), respectively.
The PET parameters of all patients, patients with patho-
logic N0 and patients with pathologic N1, 2 were de-
scribed in Table 3. Forty (28.8 %) patients showed MTV
and TLG values of 0, because the SUVmax of the pri-
mary tumor was less than 2.0. Among those patients
with MTV and TLG values of 0, no patient showed
nodal metastasis.
In the ROC curve analysis, the AUC of MTV for oc-
cult lymph node metastasis (N1 and N2) was the highest
compared with the AUCs of SUVmax and TLG (Fig. 2).
The optimal cut-off values were 3.250 (sensitivity 83.3 %,
specificity 60 %), 3.055 (sensitivity 75.0 %, specificity
67.8 %), and 9.829 (sensitivity 75.0 %, specificity 71.3 %)
for SUVmax, MTV and TLG, respectively.
Risk factors for occult lymph node metastasis
In univariate analysis, tumor size, SUVmax, MTV and
TLG were found to be significant risk factors for occult
lymph node metastasis (Table 4). Adenocarcinoma, poor
differentiation, pleural dimpling and the number of
dissected lymph nodes were not deemed risk factors for
occult lymph node metastasis in our data.
The variance inflation factor (VIF) was calculated to
investigate collinearity between tumor size and PET pa-
rameters, and was found to be 1.15 between tumor size
and SUVmax, 1.17 between tumor size and MTV, and
1.15 between tumor size and TLG. Because all VIFs
were < 4, collinearity between tumor size and various
PET parameters was not observed.
Based on the VIFs and univariate analysis results, three
different multivariate logistic regression models were
established to compare the predictive power of each
PET parameter. For model 1, which included tumor size,
differentiation, number of dissected lymph nodes and
SUVmax, the only risk factor for occult lymph node
Fig. 1 Images of a 60-year-old female patient with adenocarcinoma. The primary tumor size measured on chest CT was 2.4 cm. a Transaxial PET/
CT fusion image shows a hypermetabolic pulmonary nodule in the right upper lobe. The SUVmax, MTV and TLG of the primary tumor were 4.3,
3.5 cm3, and 9.9, respectively. b and c Transaxial PET/CT fusion image and maximum-intensity-projection image showing no significant FDG
uptake suggestive of metastasis; however, right hilar lymph node metastasis was confirmed after surgery
Table 2 Area under the curve of MTV and TLG measured by
fixed value of various SUVmax 0
Variables Area under the curve
MTV 1.5 0.775 (0.677 ~ 0.872)
TLG 1.5 0.767 (0.672 ~ 0.863)
MTV 2.0 0.783 (0.691 ~ 0.875)
TLG 2.0 0.775 (0.685 ~ 0.866)
MTV 2.5 0.756 (0.654 ~ 0.857)
TLG 2.5 0.752 (0.650 ~ 0.853)
MTV 3.0 0.728 (0.612 ~ 0.844)
TLG 3.0 0.721 (0.605 ~ 0.836)
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metastasis was found to be SUVmax (increase of 1 unit,
odds ratio [OR] = 1.120). For model 2, which included
MTV, differentiation, number of dissected lymph nodes
and tumor size in the analysis, MTV (increase of 1 cm3,
OR = 1.117) was also found to be the only risk factor for
occult lymph node metastasis. For model 3, which in-
cluded TLG, differentiation, the number of dissected
lymph nodes and tumor size, TLG (increase of 1 unit,
OR = 1.018) was not found to be a significant risk factor
for occult lymph node metastasis (Table 4).
The C-index was calculated for each multivariate lo-
gistic regression model. The C-indices of models 1, 2
and 3 were 0.718 (95 % CI 0.616 – 0.862), 0.763 (95 %
CI 0.660 – 0.856), and 0.726 (95 % CI 0.618 – 0.834), re-
spectively (Table 4). The C-indices of the MTV model
(model 2) showed the highest C-index, even though stat-
istical significances were not observed.
Discussion
This present study demonstrated that the MTV of a pri-
mary tumor is an important predictor of lymph node
metastasis in small-sized and clinically node-negative
NSCLC. MTV showed a better predictive performance
than that of SUVmax or TLG, although the differences
were not found to be statistically significant. This study
may be the first investigation of the predictive value of
volume-based parameters on lymph node metastasis in
small-sized and peripheral NSCLC. Our results suggest
that MTV helps indicate adequate surgical extent and
identify possible candidates for sublobar resection.
Anatomic resection, such as lobectomy and medias-
tinal lymph node dissection, has been regarded as the
default surgery for several decades [17], and sublobar re-
section, such as wedge resection and segmentectomy,
has been performed selectively in patients with old, with
poor lung function and early-stage NSCLC [7]. The
question has recently arisen as to whether sublobar re-
section is an oncologically valid procedure. Several retro-
spective studies and recent meta-analyses have reported
that anatomic segmentectomy could offer similar out-
comes compared with lobectomy, in terms of both over-
all and disease-free survival [18]. Even though there has
been no exact consensus on the indications for sublobar
resection, several criteria have been suggested: con-
firmed stage IA disease only, small tumors up to 2–3 cm
in diameter and a peripheral tumor location within the
lung [17]. In addition, the presence of nodal metastasis
is also important; if nodal metastasis is present, lobec-
tomy and mediastinal lymph node dissection, instead of
sublobar resection, is mandatory. Therefore some thor-
acic surgeons insist that intraoperative frozen sections
should be examined for all hilar and lobe-specific medi-
astinal lymph nodes to confirm the intraoperative N sta-
ging as N0 during sublobar resection [1, 4, 6]. However,
intraoperative examination of many lymph nodes is un-
realistic and difficult for thoracic surgeons and patholo-
gists in the clinical setting. If pN0 can be predicted from
preoperative information, sublobar resection without
strict intraoperative lymph node assessment can be per-
formed in patients with early NSCLC [8]. Tsutani et al.
reported solid tumor size and SUVmax as significant in-
dependent predictors of nodal involvement in clinical
stage IA lung adenocarcinoma; a solid tumor size <
0.8 cm on HRCT or an SUVmax < 1.5 on FDG-PET/CT
may be helpful for avoiding systematic lymphadenec-
tomy [8]. However, the AUC for SUVmax on ROC curve
analysis in a previous study was only 0.761 (95 % CI
0.703-0.819). Therefore, accurate parameters other than
SUVmax and solid tumor size are needed.
The clinical significance of volume-based PET param-
eters has been widely investigated in NSCLC [9–14, 19,
Table 3 PET parameters of 139 patients
Variables All patients (n = 139) Pathologic N0 (n = 115) Pathologic N1 and N2 (n = 24) P valuea
SUVmax 4.61 ± 3.99 4.12 ± 3.85 6.95 ± 3.91 0.001
MTV 2.0 4.18 ± 6.39 3.09 ± 5.04 9.38 ± 9.22 0.003
TLG 2.0 16.13 ± 28.86 11.96 ± 23.72 36.10 ± 41.32 0.010
MTV metabolic tumor volume, TLG total lesion glycolysis
acomparison between pathologic N0 and pathologic N1, 2
Fig. 2 ROC curve of SUVmax, MTV and TLG for occult lymph
node metastasis
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20]. MTV indicates the volume of a metabolically active
tumor, and TLG is the product of the mean SUV and
MTV; thus, these parameters reflect tumor burden.
These parameters can be measured rapidly and consist-
ently in the clinical field with the advance of image ana-
lysis software. SUVmax is also a useful parameter and
may be a surrogate marker for tumor aggressiveness [21,
22]; however, it is affected by many factors and is highly
sensitive to noise [23–25]. Recent studies have demon-
strated the prognostic value of volume-based parameters
in early stage NSCLC [12–14]; therefore, tumor volume
may be important not only in advanced-stage but also
early-stage NSCLC. Regarding the prediction of lymph
node metastasis, two recent studies have been reported.
Lebioda et al. reported that izoSUV2.5 volume (the vol-
ume of primary tumor inside SUV 2.5 line) was a risk
factor for mediastinal lymph node involvement after
analyzing the 70 NSCLC patients [26]. However, they
analyzed heterogenous group of patients with cT1-4 N0-
1 lesions. Kim et al. reported that metabolic parameters
including volume-based parameters were significant pre-
dictors of occult lymph node metastasis in clinically
node-negative squamous cell lung carcinoma; this study
analyzed large-sized tumors (cT1-3 N0 NSCLC) in 63
patients [19]. However, the clinical implication of occult
lymph node metastasis is significant in cT1 NSCLC, be-
cause its absence can serve as an indication for sublobar
resection. Anatomic resection, such as lobectomy and
complete mediastinal lymph node dissection, is the
treatment of choice in cT2-3 N1-2 NSCLC. Therefore,
we focused on small peripheral NSCLC < 3 cm. As we
hypothesized, MTV showed a slightly higher AUC in the
ROC curve analysis and C-index in the multivariate ana-
lysis, which indicated a higher predictive value than that
of SUVmax in small peripheral NSCLC, even though the
statistical differences were not significant in our data. In
our study, TLG showed a lower AUC than those of
MTV and SUVmax, and these results are consistent with
a previous study reporting that TLG is not a risk factor
for nodal metastasis in multivariate analysis [19].
Even though MTV showed promising results as a pre-
dictor of occult lymph node metastasis in small NSCLC,
this study has to be interpreted with caution. SUVmax
remains a valuable predictor for detecting lymph node
metastasis and was verified in a previous study involving
a large number of patients [8]. Even though MTV
showed a slightly higher C-index than that of SUVmax,
volume-based parameters such as MTV have an import-
ant limitation. Due to the calculation method of volume-
based parameters, patients with low SUVmax could be
underestimated, based on the cut-off value. Even though
40 patients with zero MTV and TLG showed no occult
lymph node metastasis in this study, the possibility of
underestimation by volmue-based parameters has to be
kept in mind.
This study has several limitations. First, it was a retro-
spective, single-center study and the study population
was relatively small. Although the AUC and C-index of
MTV were found to be slightly higher those of SUVmax,
they were not statistically significant. These results
might originate from the small number of enrolled
patients, and thus further analysis using a sufficient
number of patients is required for exact comparisons of
the AUC and C-index. Second, the type of operation was
not uniform although patients predominantly underwent
lobectomy with mediastinal lymph node dissection. How-
ever, because all patients underwent meticulous medias-
tinal lymph node dissection, undiagnosed lymph node
metastasis might not be present. Third, pleural invasion
was not a risk factor for occult lymph node metastasis al-
though several previous studies have reported that pleural
invasion itself is a risk factor for survival after surgery
[27]. Whether pleural invasion is related to occult lymph
node metastasis needs to be evaluated in further analyses
Table 4 Univariate and multivairate analysis for occult lymph node metastasis
Multivariate analysis
Univariate analysis SUVmax model MTV model TLG model
Variable OR (95 % CI) P OR (95 % CI) P OR (95 % CI) P OR (95 % CI) P




SUVmax (1 unit increase) 1.159 (1.050-1.279) 0.003 1.120 (1.003-1.250) 0.044
MTV (1 cm3 increase) 1.131 (1.055-1.212) <0.001 1.117 (1.031-1.211) 0.007
TLG (1 unit increase) 1.022 (1.008-1.037) 0.002 1.018 (1.002-1.035) 0.031
Poor differentiation (vs. others) 2.215 (0.699-7.014) 0.176 1.473 (0.404-5.370) 0.557 0.985 (0.226 ~ 4.295) 0.984 1.202 (0.290 ~ 4.978) 0.799
Pleural dimpling (with vs. without) 1.489 (0.615-3.607) 0.378
No. of dissected LN (1 unit increase) 1.021 (0.988-1.055) 0.223
C-index 0.718 (0.616-0.820) 0.763 (0.660-0.856) 0.726 (0.618-0.834)
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using sufficient numbers of patients. Forth, we did not
perform partial volume correction in our study dealing
with small-sized tumor. However, the patients who had
the tumor less than 1.0 cm were 12 (8.6 %) in the present
study, which may not cause significant effects on our re-
sults. Finally, thin-section CT findings except tumor diam-
eter were not considered in this study. Despite these
limitations, this study is the first to analyze volume-based
parameters as risk factors for occult lymph node metasta-
sis in small and early NSCLC. In addition, the advantage
of this study lies in the use of the C-index of several
multivariate logistic regression models to compare the
importance of PET parameters as predictors of occult
lymph node metastasis.
Conclusion
The SUVmax and volume-based parameters of primary
lesions were found to be significant risk factors for nodal
metastasis in small peripheral NSCLC. MTV showed a
better predictive performance than did the other PET
parameters; therefore, MTV may be a possible indicator
for sublobar resection in clinically node-negative small-
sized NSCLC. A further study using a larger cohort of
patients is needed to validate the predictive role of these
biomarkers derived from FDG PET.
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